Moraxella Catarrhalis: Traits, Transmission, and Health Impacts

Moraxella catarrhalis is a bacterium that lives in the human respiratory tract and ranks among the leading causes of middle ear infections in young children and flare-ups of chronic obstructive pulmonary disease (COPD) in adults. Once dismissed as a harmless bystander in the nose and throat, it was reclassified as a genuine pathogen over the past few decades as evidence mounted that it drives real disease, particularly in vulnerable populations. What makes it especially interesting to researchers is not just the infections it causes on its own, but the ways it shields other bacteria from antibiotics and manipulates the immune system to stick around.

A Strictly Human Bacterium

M. catarrhalis is a gram-negative bacterium found exclusively in humans. It does not infect animals in nature, which makes it somewhat unusual among respiratory pathogens. Formerly called Branhamella catarrhalis, it went through several name changes before its current classification settled into place, aided by improved molecular diagnostic tools developed over the past two decades.¹ Under a microscope, it appears as pairs of round cells (diplococci), and in the lab it grows readily on standard culture media. It tests positive for oxidase and catalase, and a combination of these reactions along with a simple esterase test is enough to distinguish it from closely related species like commensal Neisseria.²

Genomic studies have revealed that M. catarrhalis is not a single uniform population. Analysis of nearly 2,000 genomes has identified two major lineages, referred to as serum-resistant (SR) and serum-sensitive (SS), with distinct evolutionary histories. The SR lineage has more conserved genomes and a wider variety of surface molecule types, while the SS lineage is more genetically variable overall. These lineage-level differences in surface proteins and sugar-lipid structures matter because they influence how well each strain dodges the immune system and responds to potential vaccines.³

Who Carries It and How It Spreads

Colonization of the nose and throat is extremely common in early childhood. Studies of preschool-age children have found carriage rates above 50%, with one study in Nepal detecting M. catarrhalis in about 59% of healthy kindergarteners.⁴ A Chinese study of preschool children reported a similar carriage rate of roughly 52%.⁵ Carriage drops substantially by adulthood, when most healthy people either clear the organism or carry it at levels too low to detect.⁶

M. catarrhalis spreads through respiratory droplets and direct contact, much like other upper-respiratory bacteria. Crowded settings accelerate transmission: classroom occupancy of 15 to 30 children was a significant risk factor for carriage, as was recent antibiotic use within the previous six months.⁴ The bacterium rarely travels alone. It co-colonizes with Streptococcus pneumoniae and Haemophilus influenzae at rates higher than chance would predict, while it seems to compete with Staphylococcus aureus, showing a negative association with that species in the same nasal passages. These partnerships turn out to have clinical consequences that go well beyond simple coexistence.

How It Attaches and Invades

To establish a foothold in the respiratory tract, M. catarrhalis relies on a family of surface proteins that act as molecular grappling hooks. The best-studied of these is a protein called UspA1, which sticks to human cells by binding to receptors on their surface, including fibronectin, laminin, and a family of adhesion molecules known as CEACAMs.⁷ The binding is sequence-specific, meaning small differences in UspA1 from strain to strain can change how well the bacterium grabs on. This variation partly explains why some strains colonize more effectively than others.

UspA1 is not the only adhesin in the toolkit. Another surface protein, McaP, also helps M. catarrhalis stick to human lung epithelial cells. When researchers deleted the key portion of McaP in laboratory experiments, bacterial adherence to lung cells dropped dramatically.⁸ Beyond simply clinging to the surface, M. catarrhalis can actually enter respiratory epithelial cells by triggering those cells to engulf it, a process recognized through an immune receptor called TLR2 and an intracellular sensor called NOD1.⁹ Getting inside cells may help the bacterium hide from antibiotics and immune defenses while maintaining its hold in the airway.

Dodging the Immune System

One of M. catarrhalis’s most studied survival tricks is its ability to resist complement, a cascade of blood proteins that normally punch holes in bacterial membranes. Complement-resistant strains do not actually prevent the cascade from starting. Instead, they block it at a late step, interfering with the formation of the final membrane-damaging complex. Research has shown this resistance depends on a surface protein, because removing it with an enzyme called trypsin strips away the protective effect entirely.¹⁰ The two major genomic lineages (SR and SS) diverge here: serum-resistant strains, by definition, survive in human blood serum, while serum-sensitive strains do not. This split likely influences which strains cause disease versus which are cleared quickly.

The immune system does fight back in other ways. When macrophages encounter M. catarrhalis or its shed components, they activate an internal alarm system involving an inflammasome pathway that leads to a form of rapid inflammatory cell death called pyroptosis. This response helps contain the infection by sacrificing the infected cell and releasing inflammatory signals to recruit reinforcements.¹¹ Meanwhile, the airway lining cells themselves rely on TLR2 to detect the bacterium and mount an inflammatory response. Mouse experiments have shown that animals lacking TLR2 produce fewer inflammatory signals in the lung when infected with M. catarrhalis, which sounds like it should be a good thing but actually means the immune system struggles to recognize and clear the bacteria.¹²

Ear Infections in Children

Most children experience at least one episode of middle ear infection (acute otitis media) by their third birthday, and about half suffer multiple episodes.¹³ M. catarrhalis is traditionally listed as one of the top three bacterial causes, alongside S. pneumoniae and H. influenzae. But its actual contribution to middle ear disease is lower than its high colonization rates might suggest. In a large study of over 12,000 ear infection episodes, M. catarrhalis accounted for under 5% of the pathogens recovered from middle ear fluid, compared to about 48% for H. influenzae and 43% for S. pneumoniae.¹⁴

The disconnect between how often M. catarrhalis colonizes the nose and how often it actually reaches the middle ear is striking. Among children whose nasopharynx carried M. catarrhalis during an ear infection episode, the organism was recovered from the middle ear fluid in only about 11% of cases. That rate was far lower than for S. pneumoniae or H. influenzae.¹⁵ When M. catarrhalis does cause otitis media, the infections tend to be milder than those caused by other bacteria. They are less likely to cause the eardrum to rupture, never produced mastoiditis (a serious bone infection behind the ear) in the large surveillance study, and were more often mixed infections involving a second pathogen rather than sole-pathogen infections.¹⁴

This raises a question that researchers are still working through: is M. catarrhalis’s main threat in otitis media its direct role as a pathogen, or its indirect role as an antibiotic-shielding bystander that helps other bacteria survive treatment? Evidence increasingly points toward both, with the indirect role being underappreciated.

COPD Flare-Ups in Adults

In adults, M. catarrhalis is the second most common bacterial cause of COPD exacerbations, trailing only nontypeable H. influenzae.¹⁶ A prospective study that used molecular typing to track individual strains found that about half of all new acquisitions of M. catarrhalis in COPD patients triggered a clinical exacerbation. The study estimated M. catarrhalis is responsible for roughly 10% of all COPD flare-ups, which translates to an estimated two to four million episodes per year.¹⁷

A history of M. catarrhalis infection also appears to raise the risk of future hospitalizations. In a study of COPD patients readmitted for exacerbations, prior M. catarrhalis infection was the strongest bacterial risk factor for re-hospitalization, with an odds ratio far exceeding that of H. influenzae.¹⁸ The mechanisms likely involve inflammation and tissue damage. In mice chronically exposed to cigarette smoke, M. catarrhalis infection amplified the release of enzymes and signaling molecules associated with the breakdown of lung tissue, essentially accelerating the kind of damage that leads to emphysema.¹⁹ The picture that emerges is of a pathogen that thrives in already-damaged lungs and makes a bad situation measurably worse.

Rare but Serious Invasive Disease

Outside the respiratory tract, M. catarrhalis occasionally causes bloodstream infections, endocarditis, meningitis, and other invasive diseases, though these are uncommon. The outlook for patients with M. catarrhalis endocarditis or those who have severe immune deficiencies, particularly immunoglobulin deficiency or neutropenia unrelated to blood cancer, is poor.²⁰ These cases are rare enough that most clinicians will see few in a career, but they serve as a reminder that this bacterium can cross compartment boundaries in immunocompromised hosts.

An Antibiotic Resistance Problem That Started Decades Ago

One of the most clinically relevant features of M. catarrhalis is its near-universal resistance to penicillin-type antibiotics. Well over 90% of isolates now produce a beta-lactamase enzyme that chews up penicillins and amoxicillin before they can work.¹ In a large European surveillance study, 92% of M. catarrhalis strains were beta-lactamase positive.²¹

The enzyme responsible comes in two forms, BRO-1 and BRO-2, which differ slightly in their properties. BRO-1 is more common and confers a higher level of resistance.²² Gene-knockout experiments confirmed that the single beta-lactamase gene (bla) is solely responsible for penicillin resistance in M. catarrhalis, meaning there is no backup system in play.²³ From a treatment standpoint, this means plain amoxicillin is unreliable against M. catarrhalis. Amoxicillin combined with a beta-lactamase inhibitor (like clavulanic acid) works, as do certain cephalosporins and macrolides. The resistance picture for M. catarrhalis itself is manageable, but the real complication comes from what happens next.

Shielding Neighboring Bacteria from Antibiotics

Perhaps the most underappreciated aspect of M. catarrhalis biology is its ability to protect other, antibiotic-susceptible bacteria from being killed by penicillins. This “indirect pathogenicity” has been demonstrated in multiple experimental systems and has direct implications for treatment failures in respiratory infections.

In a mouse pneumonia model, animals infected with a lethal dose of pneumococci (S. pneumoniae) that should have been cured by penicillin died when they were simultaneously co-infected with beta-lactamase-producing M. catarrhalis. The M. catarrhalis broke down the antibiotic in the local environment, leaving the pneumococci free to multiply and kill the mice. When a beta-lactamase-negative strain of M. catarrhalis was used instead, no protection occurred, and treatment with amoxicillin plus a beta-lactamase inhibitor (clavulanic acid) overcame the problem.²⁴ In continuous-culture biofilm models, growing pneumococci alongside beta-lactamase-producing M. catarrhalis elevated the effective resistance of S. pneumoniae to penicillin-class drugs.²⁵

This protection is not limited to direct contact between the bacteria. M. catarrhalis sheds tiny bubble-like particles from its outer membrane, called outer membrane vesicles (OMVs), and these vesicles carry active beta-lactamase. Lab experiments showed that OMVs at low concentrations completely broke down amoxicillin within an hour, and that pre-incubating amoxicillin with these vesicles fully rescued not only M. catarrhalis itself but also amoxicillin-susceptible S. pneumoniae and H. influenzae from antibiotic killing.²⁶ In practical terms, M. catarrhalis does not even need to be physically adjacent to the target pathogen to shield it; the vesicles can diffuse through the surrounding fluid and neutralize the drug at a distance.

Biofilms and Community Living

In the respiratory tract, M. catarrhalis rarely lives as free-floating individual cells. Like many chronic infection-causing bacteria, it forms biofilms, structured communities encased in a sticky matrix that are far harder for antibiotics and immune cells to penetrate. Within polymicrobial biofilms containing both M. catarrhalis and pneumococci, the antibiotic protection runs both directions: M. catarrhalis shields pneumococci from penicillins through its beta-lactamase, and pneumococci increase the resistance of M. catarrhalis to macrolide antibiotics. Beyond antibiotic protection, pneumococci enhanced M. catarrhalis colonization in animal models through a quorum-sensing mechanism, and co-infection affected whether pneumococci spread to the middle ear.²⁷

The outer membrane vesicles released by M. catarrhalis also play roles within biofilms. Genomic analyses have found that M. catarrhalis genomes are enriched in OMV-associated protein genes compared to related Moraxella species isolated from animals, suggesting these vesicle components were acquired relatively recently in evolutionary terms and may have been key to the bacterium’s adaptation to the human host.²⁸ OMV proteins participate in complement evasion, adhesion, immune misdirection, antibiotic destruction, and biofilm formation, essentially acting as a multifunctional weapons package that M. catarrhalis can deploy without leaving its biofilm fortress.

Why There Is No Vaccine Yet

Given that M. catarrhalis causes millions of ear infections in children and millions of COPD flare-ups in adults each year, you might expect an active vaccine program. Several promising target molecules have been identified, many of them the same surface proteins discussed above: UspA1, UspA2, and other outer membrane components that play roles in adhesion and serum resistance.²⁹ The strategy of targeting molecules that contribute to serum resistance is appealing because disabling them would make the bacterium vulnerable to the body’s own complement system.³⁰

But vaccine development for M. catarrhalis has been slow. Several obstacles contribute. The strain diversity described earlier means a vaccine targeting one version of UspA1 might not protect against strains carrying a different variant. The bacterium’s exclusive residence in humans means animal models are imperfect stand-ins for testing. And because M. catarrhalis infections, while numerous, are usually not life-threatening, the commercial incentive for an expensive vaccine development program is weaker than for deadlier pathogens. As of now, promising antigens have been tested in animal models, but human clinical trials remain in the early planning stages.

What Smoking Does to the Equation

Cigarette smoke independently damages the airways, stripping cilia from the bronchial lining and impairing the lung’s ability to sweep bacteria out. When M. catarrhalis infection is layered on top of chronic smoke exposure, the damage compounds. In a mouse model of long-term cigarette smoke exposure, adding M. catarrhalis infection significantly increased levels of enzymes (MMP9 and MMP12) that break down the structural proteins of lung tissue. It also boosted a signaling molecule (EMAPII) associated with endothelial cell death, regardless of whether the animals had been exposed to smoke.¹⁹ The combination of smoke-damaged airways and M. catarrhalis infection appeared to accelerate the molecular processes underlying emphysema more than either insult alone. This is a pilot study, so the findings need confirmation, but they align with the clinical observation that COPD patients who keep acquiring M. catarrhalis tend to have worse outcomes over time.